SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Meta Expands AI Training With Employee Activity Tracking Tools 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
SAN DIEGO, March 07, 2016 -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three and twelve months ended December 31, 2015, before the opening of trading on Monday, March 14, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Monday, March 14. The call will be open on a listen-only basis to any interested parties. The company will also provide a business update, including details on independent and partnered development programs in the conference call and webcast.
Conference Call
To listen to the conference call, dial in approximately ten minutes before the scheduled call to (719) 325-2494 (preferred), or (888) 576-4398 (toll-free), and reference confirmation code 2761479. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (719) 457-0820 (preferred) or (888) 203-1112 (toll-free) and enter replay passcode 2761479. The call also will be available live and archived through the events page at www.vical.com.
Invited participants may ask questions during the conference call. Others may submit questions before the call by e-mail addressed to [email protected] or by fax to (858) 646-1150. Submitted questions will be screened for appropriateness and general interest. Selected questions received with sufficient notice before the call will be answered as time permits at the end of the call. For further information, contact Vical’s Investor Relations department by phone at (858) 646-1127 or by email at [email protected].
About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com.
Contact: Andrew Hopkins (858) 646-1127 Website: www.vical.com
